Advertisement
Mr. Granadillo served as Senior Vice President for Eli Lilly and Company("Lilly") until 2004 when he retired after 34 years of service. He was memberof Lilly's Policy Committee, which was comprised of its top seven executives.As Lilly's top human resources, manufacturing and quality executive, he wasresponsible for policies affecting a global workforce of more than 45,000employees, as well as, a broad network of manufacturing facilities for itsextensive line of products. Mr. Granadillo led initiatives that brought Lillywide recognition as a progressive employer. He also oversaw more than 20 sitesand 13,000 employees involved in the manufacturing of Lilly's conventional"small-molecule" pharmaceuticals and "large-molecule" biotech therapies.
Advertisement
"Pedro's appointment brings to the Board three decades of industryknowledge and extensive pharmaceutical development and management experience,"said Edmundo Muniz, Chief Executive Officer of Tigris. "His past experienceand proven track record in corporate management, human resources,manufacturing and quality assurance will be instrumental as we drive ourclinical and preclinical programs forward."
"I am excited to be joining Tigris at this important time in the Company'sdevelopment," said Mr. Granadillo. "I look forward to working with themanagement team, the Board and the Company's investors in implementing theCompany's strategic business plans over the next year and beyond."
Mr. Granadillo is currently a member of the boards of directors ofHaemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL;and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S.degree in Industrial Engineering from Purdue University.
About Tigris Pharmaceuticals, Inc.
Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical companythat develops therapeutic technologies to treat oncology, infectious diseasesand other areas of unmet medical need. Tigris is currently conducting a PhaseII clinical study for A-007, its topical treatment for pre-cancerous andcancerous anogenital lesions associated with HPV. Tigris is also developingthree novel, targeted small molecule oncology compounds. Tigris' mission isto efficiently move its existing and future technologies through the variousstages of clinical development in order to meet patients' needs for safe andeffective treatments of human illnesses.
This news release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Such statements arevalid only as of today, and we disclaim any obligation to update thisinformation. These statements are subject to known and unknown risks anduncertainties that may cause actual future experience and results to differmaterially from the statements made. These statements are based on our currentbeliefs and expectations as to such future outcomes. Drug discovery anddevelopment involve a high degree of risk. Factors that might cause such amaterial difference include, among others, uncertainties related to theability to attract and retain partners for our technologies, theidentification of lead compounds, the successful preclinical developmentthereof, the completion of clinical trials, the FDA review process and othergovernmental regulation, our pharmaceutical collaborator's ability tosuccessfully develop and commercialize drug candidates, competition from otherpharmaceutical companies, product pricing and third party reimbursement, andother factors described in our filings with the Securities and ExchangeCommission.Contact: Anne White Chief Operating Officer Tigris Pharmaceuticals, Inc. (239) 444-5400
